Emmaus Life Sciences, Inc. (EMMA) stock
EMMAOTCPharmaceutical PreparationsFiscal year ends December 31
$0.05−0.01 (-14.38%)
Close on Oct 19, 2026Market cap $6.03MP/E –Yield –
Emmaus Life Sciences r&d expenses
Research and development expenses are spending on new products and technology.
Emmaus Life Sciences's R&D Expenses for the twelve months ending Jun 30, 2026 was $237.00K. For fiscal 2025 it was $313.00K, down 52.4% from the year before. The highest annual figure on record is $4.11M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $313.00K | -52.4% |
| FY2024 | Dec 31, 2024 | $657.00K | -44.7% |
| FY2023 | Dec 31, 2023 | $1.19M | -31.1% |
| FY2022 | Dec 31, 2022 | $1.73M | -58.0% |
| FY2021 | Dec 31, 2021 | $4.11M | +70.7% |
| FY2020 | Dec 31, 2020 | $2.41M | +10.3% |
| FY2019 | Dec 31, 2019 | $2.18M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | $116.00K | -15.3% |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | $40.00K | -72.6% |
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $31.00K | -83.8% |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $50.00K | -72.7% |
| Q4 FY2024CQ4 2024 | Dec 31, 2024 | $137.00K | -17.5% |
| Q3 FY2024CQ3 2024 | Sep 30, 2024 | $146.00K | -64.7% |
| Q2 FY2024CQ2 2024 | Jun 30, 2024 | $191.00K | -40.3% |
| Q1 FY2024CQ1 2024 | Mar 31, 2024 | $183.00K | -36.7% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $166.00K | -68.6% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $414.00K | -4.2% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $320.00K | +7.4% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $289.00K | -38.0% |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | $529.00K | -50.9% |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | $432.00K | -8.1% |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | $298.00K | -60.4% |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | $466.00K | -74.2% |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | $1.08M | +88.1% |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | $470.00K | -25.3% |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | $753.00K | +27.8% |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | $1.81M | +193.2% |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | $573.00K | -49.3% |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | $629.00K | +16.5% |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | $589.00K | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | $617.00K | – |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $1.13M | – |
| Q3 FY2019CQ3 2018 | Jun 30, 2019 | $540.00K | – |
See a number that looks wrong?